Expert consensus report on lipid mediators: Role in resolution of inflammation and muscle preservation.
Level 5 - mechanism / opinion, no new human data
Expert consensus report based on narrative review and mechanistic reasoning with no new clinical data reported.
PubMed 38805158 · doi:10.1096/fj.202400619R
What was done
An expert consensus panel met to review the biological mechanisms and clinical rationale for using fish-oil-enriched lipid emulsions in parenteral nutrition, focusing on omega-3 polyunsaturated fatty acids (EPA and DHA) and their downstream specialized pro-resolving mediators (SPMs) in modulating inflammation and muscle preservation.
What was found
The abstract reports consensus opinions and mechanistic rationale without quantitative empirical data or statistical metrics. The panel reached unanimous agreement supporting the proactive clinical use of fish-oil-enriched lipid emulsions to deliver EPA and DHA precursors for SPMs, preserve muscle mass, and promote active inflammation resolution without suppressing host defense during critical illness, surgery, or immobility.
Why it matters
The statement advocates moving beyond viewing parenteral lipid emulsions solely as caloric sources toward using fish-oil-derived omega-3 formulations as therapeutic agents to aid recovery in catabolic and inflammatory states.
Limits
This is a narrative expert consensus report rather than a systematic review or primary clinical trial. The abstract provides no specific quantitative outcomes, sample sizes, effect estimates, dosing recommendations, or safety event rates.
Cited by
- supports Metabolites of EPA and DHA include resolvins and protectins, which function to resolve inflammatory processes.